nasus-post

Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of TaffixTM Intranasal Antiviral Protection Against SARS-CoV-2- in

Tel Aviv , Israel, October 13, 2020 – Nasus Pharma a privately held clinical-stage
biopharmaceutical company developing a powder-based intranasal (PBI) product
portfolio to address acute medical conditions and public health threats, today
announced data from a prospective clinical post marketing users survey
demonstrating that TaffixTM, the Company’s innovative nasal powder inhaler that
effectively blocks viruses from reaching nasal mucosa, was able to reduce
infection rate of SARS-CoV-2 virus after super spread event by at least 4 fold.
Nasus’s user survey was conducted in Bney Brak- a city that tops Israel’s list of
COVID-19 infection and mortality. Members of a synagogue community were
offered the use of Taffix and instructed to use it when approaching a highly
populated environment. The survey was planned ahead of Rosh Hashana ( the
Jewish new year) – an event that involved many hours spent in close proximity
among prayers for at least 7 hours each day for 2 consecutive days and was
defined as a super spread event. Users and non users among the synagogue
community were followed up to 14 days after the event. Rate of infection among
non users was 10% ( 16/160,) while rate of infection among Taffix users was
2.4% ( 2/83 ITT, p=0.037) or 0% ( 0/81 PP p=0.002). At the same time period
the general infection rate in the city of Bney Brak increased by some 60%,
“These important results conform with prior in vitro studies performed with
TaffixTM that proved its robust activity against the transmission of SARS -CoV-2 ,”
said Dr. Dalia Megiddo, Chief Executive Officer of Nasus Pharma. “ This is the
first clinical real life data showing that the use of Taffix is highly effective even in
the worst-case scenario of a super spread event in the heart of the worst hit city
in Israel. Reducing the infection risk by 75% or even 100% can dramatically
change the means to fight the worst epidemic humanity have witnessed in close
to a 100 years” .
Prof Y. Naparstek, from the Hadassah Medical Center , Jerusalem Israel, and
the Scientific Director of Meuhedet HMO Research Institute In Israel added:
“The fact that Taffix was able to significantly reduce infection rate in users of the
product is very encouraging. It may offer an additional layer of protection to
people who encounter events that pose high risk of infection. The data
contributes to our knowledge of the effect on population protection. Additional
controlled clinical studies will be needed to deepen our understanding of the
specific efficacy in different circumstances.”
Udi Gilboa, Executive Chairman of the Board of Nasus Pharma added, “This
promising clinical data reinforces the potential of TaffixTM to become an important
solution and the leading additional layer of protection that will enable the

resuming of social and economic activities in a much safer manner.
With a global challenge to create a new normality while living side by side with
the pandemic, we believe TaffixTM can be an important clinically-proven tool
offering an additional safety measure to our users and customers. Based on our
very encouraging clinical findings, we believe Taffix which is now available
globally in many parts of the world, will be used on a daily basis in crowded
environment (Tube or Subway, trains, offices, supermarkets, flights, restaurants
etc) and will be key to a personal protection activity as well as part of the public
health initiatives to create safer and better protected daily routines”.
TaffixTM, currently approved for marketing as a protective mechanical barrier
against allergens and viruses (e.g., SARS-CoV-2) within the nasal cavity
in Europe and to block inhaled viruses and bacteria within the nasal cavity in
Israel, was developed to create an acidic microenvironment in the nose which is
proven to prevent viruses from entering and infecting nasal cells. There is a
growing body of evidence that suggests the nose is the main gateway of airborne
droplet viral infection to the body for viruses, including SARS-COV-2. TaffixTM
powder creates a unique thin acidified gel above the nasal mucosa that lasts 5
hours, significantly shielding the nasal cells from inhaled viruses through both
mechanical and chemical protection. As such Taffix may be an important new
protective tool for preventing SARS-COV-2 viral infections in addition to the
multiple preventive measures taken today. The results of this prospective survey
will be submitted to publication in the near future.
About Nasus Pharma:
Based on its unique microsphere technology Nasus Pharma is developing a
number of intranasal powder products aimed at assisting patients in several
acute emergency situations such as opioid overdose and anaphylactic shock.
Intranasal administration is most suitable for those situations in which rapid drug
delivery is required and offers multiple advantages such as rapid drug delivery,
ease of use, non-invasiveness, and safety. Nasus portfolio comprises a number
of programs: Intranasal Naloxone (heading to phase 3) and Intranasal
Epinephrine (phase 2) as well as a number of preclinical POC programs.
Contact:
Info@nasuspharma.com

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email